We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · August 09, 2021

Remetinostat Gel Promising for Basal Cell Carcinoma

Overall response rate of 69.7 percent seen with topical HDAC inhibitor; complete resolution observed for 54.8 percent of tumors on pathologic exam

HealthDay

 

Further Reading